Ikarian Capital’s BridgeBio Pharma BBIO Stock Holding History

Ikarian Capital’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-58,500	Closed	-$4.34M	–	160
2026 Q1	$4.34M	Buy	+58,500	New	+$4.24M	0.35%	65
2025 Q2	–	Sell	-655,400	Closed	-$22.7M	–	140
2025 Q1	$22.7M	Sell	655,400 -44,600	-6%	-$1.5M	2.79%	5
2024 Q4	$19.2M	Buy	+700,000	New	+$18.1M	2.61%	7
2024 Q3	–	Sell	-6,000	Closed	-$15.2M	–	156
2024 Q2	$15.2M	Sell	6,000 -383,400	-98%	-$10.5M	2.65%	11
2024 Q1	$12M	Buy	+389,400	New	+$13.2M	1.32%	22
2023 Q4	–	Sell	-3,054	Closed	-$8.05M	–	143
2023 Q3	$8.05M	Sell	3,054 -1,226,746	-100%	-$34.8M	0.97%	31
2023 Q2	$21.2M	Buy	1,229,800 +680,200	+124%	+$10.2M	3.37%	3
2023 Q1	$9.11M	Buy	+549,600	New	+$6.41M	2.07%	11
2022 Q3	–	Sell	-200,000	Closed	-$1.82M	–	115
2022 Q2	$1.82M	Buy	+200,000	New	+$1.67M	0.33%	62
2022 Q1	–	Sell	-100,000	Closed	-$1.67M	–	200
2021 Q4	$1.67M	Buy	+100,000	New	+$4.23M	0.25%	74
2020 Q3	–	Sell	-31,500	Closed	-$1.03M	–	181
2020 Q2	$1.03M	Buy	+31,500	New	+$959K	0.08%	123

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Ikarian Capital's BBIO Position: Q2 2026 in Review

Ikarian Capital reduced its BridgeBio Pharma (BBIO) stake by 64% in Q2 2026, selling an estimated $7.19M and leaving 57,417 shares worth $4.28M. The position accounts for 0.46% of the portfolio, ranked #62.

Ikarian Capital first reported a position in BBIO in Q1 2020 and has held it in 14 quarters since. The position peaked at $19.1M in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Ikarian Capital held 57,417 shares of BridgeBio Pharma worth $4.28M as of Q2 2026.
Ikarian Capital sold 102,703 BridgeBio Pharma shares in Q2 2026, an estimated $7.19M.
BridgeBio Pharma made up 0.46% of Ikarian Capital's portfolio in Q2 2026, its #62 holding.
Ikarian Capital first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 14 quarters since.
Ikarian Capital's BridgeBio Pharma position peaked at $19.1M in Q4 2023.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.